• PRS77 - SOCIOECONOMIC DETERMINANTS OF SMOKING IN GREECE

    Oct 1, 2018, 00:00

  • PHP23 - COMPARING RISK SHARING AGREEMENTS IN CATALONIA WITH OTHERS EU COUNTRIES

    Oct 1, 2018, 00:00

  • PRS7 - PROPHYLACTIC VERSUS SELECTIVE USE OF SURFACTANT IN PRETERM INFANTS IN KOREA - KOREAN NEONATAL NETWORK

    Oct 1, 2018, 00:00

  • PRM237 - PERFORMANCE OF PROPENSITY SCORE MATCHING IN SMALL SAMPLES - SIMULATION STUDY

    Oct 1, 2018, 00:00

  • PCN292 - CANCER DRUGS IN GERMANY- HTA DECISIONS OF NEW AND INNOVATIVE ONCOLOGY DRUGS IN GERMANY – AN ANALYSIS USING THE PRISMACCESS® DATABASE

    Oct 1, 2018, 00:00

  • PMD86 - POTENTIAL COST-EFFECTIVENESS OF SPECTRAL PHOTON-COUNTING COMPUTED TOMOGRAPHY (SPCCT) VERSUS CT COMBINED TO CT ANGIOGRAPHY (CTA) IN THE IDENTIFICATION AND TREATMENT OF ISCHAEMIC STROKE PATIENTS IN THE UK

    Oct 1, 2018, 00:00

  • PHP244 - BRIDGING THE GAP- ENSURING FAIR ASSESSMENT OF ORPHAN TREATMENTS BY HEALTH TECHNOLOGY ASSESSMENTS IN ENGLAND

    Oct 1, 2018, 00:00

  • PMD97 - TECHNOLOGICAL-ECONOMIC COMPARISON OF ENDODONTICS TECHNIQUE WITH FOCUS ON NIKL-TITAN SYSTEMS

    Oct 1, 2018, 00:00

  • PMD151 - SURGICAL TREATMENT, COMPLICATIONS, HEALTH CARE RESOURCE UTILIZATION AND COSTS AMONG PATIENTS WITH ACROMIOCLAVICULAR DISLOCATIONS

    Oct 1, 2018, 00:00

  • PSY93 - COST EFFECTIVENESS OF LETERMOVIR AS PROPHYLAXIS OF CLINICALLY SIGNIFICANT CYTOMEGALOVIRUS REACTIVATION AND DISEASE IN ADULT CMV-SEROPOSITIVE ALLOGENEIC HAEMATOPOIETIC STEM CELL TRANSPLANT- AN ENGLISH PAYER PERSPECTIVE

    Oct 1, 2018, 00:00

  • PRM7 - THE USE OF NATURAL LANGUAGE PROCESSING TO ASSESS PATIENTS WITH BLEEDS IN THEIR NOTES IN THE OPTUM EHR DATABASE

    Oct 1, 2018, 00:00

  • PMD111 - THE COST-EFFECTIVENESS OF BIMODAL AIDING COMPARED TO UNILATERAL AND BILATERAL COCHLEAR IMPLANT USE IN ADULTS WITH BILATERAL SEVERE TO PROFOUND DEAFNESS

    Oct 1, 2018, 00:00

  • PND126 - SYSTEMATIC REVIEW OF THE BURDEN OF PEDIATRIC MULTIPLE SCLEROSIS IN NORTH AMERICA AND EUROPE

    Oct 1, 2018, 00:00

  • PSY208 - PATIENTS’ PREFERENCES FOR PSORIASIS TREATMENT BASED ON A DISCRETE CHOICE EXPERIMENT. COEPSO STUDY

    Oct 1, 2018, 00:00

  • PUK35 - WORK PRODUCTIVITY AND EQ-5D UTILITY OF PATIENTS WITH CHRONIC KIDNEY DISEASE BY ANEMIA SEVERITY- POOLED RESULTS FROM THREE CROSS-SECTIONAL INTERNATIONAL SURVEYS

    Oct 1, 2018, 00:00

  • PSY111 - PHARMACOECONOMIC EVALUATION OF BIOSIMILAR RECOMBINANT ALPHA-EPOETIN IN THE TREATMENT OF ANEMIA IN HEMODIALYSIS PATIENTS

    Oct 1, 2018, 00:00

  • PMH40 - COST-MINIMISATION ANALYSIS OF SECOND GENERATION LONG ACTING INJECTABLES (RISPERIDONE , PALIPERIDONE, AND ARIPIPRAZOLE) FOR SCHIZOPHRENIA IN SPANISH MEDIUM-LONG TERM CARE PSYCHIATRIC UNITS

    Oct 1, 2018, 00:00

  • PMD128 - ECONOMIC AND CLINICAL OUTCOMES AMONG PATIENTS WITH ACUTE ISCHEMIC STROKE- A RETROSPECTIVE ANALYSIS OF US HOSPITAL DATABASE

    Oct 1, 2018, 00:00

  • PND10 - GENIUS RWE STUDY (FINGOLIMOD REAL WORLD EVIDENCE ITALIAN MULTICENTER OBSERVATIONAL STUDY IN MULTIPLE SCLEROSIS)PRELIMINARY RESULTS

    Oct 1, 2018, 00:00

  • PMU46 - IN-HOSPITAL ECONOMIC BURDEN OF ANASTOMOTIC LEAKAGE AFTER COLORECTAL ANASTOMOSIS SURGERY- A REAL-WORLD COST ANALYSIS

    Oct 1, 2018, 00:00

  • PRM44 - DIFFERENTIATING DISCOUNT RATES IN COST-EFFECTIVENESS EVALUATIONS IN THE CONTEXT OF GENE THERAPIES.

    Oct 1, 2018, 00:00

  • PMD45 - BIOMARKER-GUIDED RISK ASSESSMENT OF ACUTE KIDNEY INJURY- RESULTS OF A COSTING MODEL FROM A UK NHS PERSPECTIVE

    Oct 1, 2018, 00:00

  • PHP281 - THE METHODOLOGICAL DIFFERENCES OF EUROPEAN JOINT ASSESSMENT AND GERMAN HTA- AN EMPIRICAL APPROACH

    Oct 1, 2018, 00:00

  • PND31 - COST ANALYSIS OF BOTULINUM TOXIN A (BOTOX® AND XEOMIN®) IN REAL-WORLD CLINICAL PRACTICE

    Oct 1, 2018, 00:00

  • PMD165 - EVALUATING DIGITAL HEALTH TECHNOLOGIES- A REVIEW OF HTA GUIDANCE AND ASSESSMENTS IN EUROPE

    Oct 1, 2018, 00:00

  • PMU111 - BEST PRACTICE METHODS AND CONSIDERATIONS FOR THE DEVELOPMENT, EVALUATION, AND IMPLEMENTATION OF INTERVIEWER-ADMINISTERED PATIENT-REPORTED OUTCOMES (ADPROS)

    Oct 1, 2018, 00:00

  • PDB84 - HETEROGENEITY OF TREATMENT EFFECT IN THE DIABETES PREVENTION PROGRAM- HIGH BASELINE RISK OF DEVELOPING DIABETES MAY PROVIDE A PLACE FOR METFORMIN IN DIABETES PREVENTION THAT USING OVERALL SAMPLE AVERAGE COSTS AND EFFECTS CONCEALS

    Oct 1, 2018, 00:00

  • PMD76 - WHICH INTENSIVE CARE ANALYTICS ARE A WORTHWHILE INVESTMENT FOR DEVELOPERS? AN EARLY HEALTH TECHNOLOGY ASSESSMENT.

    Oct 1, 2018, 00:00

  • PMU102 - A MULTIVARIATE APPROACH THAT ALLOWS COMPREHENSIVE SCORING OF MULTI-FACETED CONCEPTS- FOCUS ON MEDICINE ACCEPTABILITY IN VULNERABLE POPULATIONS

    Oct 1, 2018, 00:00

  • PCV127 - EFFECT OF LIPID TESTING INTERVAL ON CARDIOVASCULAR DISEASE AMONG NEWLY DIAGNOSED DYSLIPIDEMIA PATIENTS

    Oct 1, 2018, 00:00

  • PCN231 - PRICING, AVAILABILITY, AFFORDABILITY, PRICE COMPONENTS OF ESSENTIAL ANTICANCER MEDICINES IN ADDIS ABABA, ETHIOPIA

    Oct 1, 2018, 00:00

  • PCN329 - OUTCOMES-BASED ARRANGEMENTS IN ONCOLOGY- A LANDSCAPE ANALYSIS

    Oct 1, 2018, 00:00

  • PCN30 - EVIDENCE GENERATION IN A EARLY ACCESS STRATEGY FOR TARGETED ONCOLOGY THERAPIES- A COMPARISON IN NON-SMALL CELL LUNG CANCER

    Oct 1, 2018, 00:00

  • PRM99 - TRENDS IN OPIOID PRESCRIBING IN PRIMARY CARE PHYSICIAN OFFICES IN THE UNITED STATES- 2006-2015

    Oct 1, 2018, 00:00

  • PMU88 - HEALTH EXPECTANCIES FROM CLINICAL DATA- AN ALTERNATIVE TO THE SULLIVAN METHOD?

    Oct 1, 2018, 00:00

  • PDB120 - EVALUATION OF HEALTH STATUS OF TYPE 2 DIABETES OUTPATIENTS RECEIVING CARE IN A TERTIARY HOSPITAL IN NIGERIA

    Oct 1, 2018, 00:00

  • PMU14 - COMPARISON TO STANDARD OF CARE- MODELISATION OF POTENTIAL SELECTION BIAS FOR ACTIVE REFERENCE IN RANDOMISED CLINICAL TRIALS

    Oct 1, 2018, 00:00

  • PHP284 - TIME TO HTA DECISION FOR INTERNATIONALISED MEDICINES IN AUSTRALIA, CANADA AND EUROPE

    Oct 1, 2018, 00:00

  • PRM171 - DETERMINANTS OF THE ACCEPTABILITY OF HEALTH PROBLEMS IN DIFFERENT AGES- EXPLORING A NEW APPLICATION OF THE EQ VAS

    Oct 1, 2018, 00:00

  • PMU69 - DESCRIPTION OF HEALTH CARE ACTIVITY OF A NUTRITION AREA MANAGED BY A HOSPITAL PHARMACY SERVICE

    Oct 1, 2018, 00:00

  • PCP69 - APPLICATION DECREE OF JARDE LAW- EXPERIENCE FROM A NON-INTERVENTIONAL STUDY IN FRANCE

    Oct 1, 2018, 00:00

  • PHP27 - EFFECTIVENESS OF COMMUNITY-BASED INTERVENTIONS FOR THE PREVENTION AND TREATMENT OF MENTAL HEALTH PROBLEMS AND MENTAL DISORDERS IN THE GENERAL POPULATION- SYSTEMATIC REVIEW

    Oct 1, 2018, 00:00

  • PCN152 - COST EFFECTIVENESS OF ALECTINIB IN THE FIRST LINE TREATMENT OF ADVANCED ALK-POSITIVE NON-SMALL CELL LUNG CANCER IN TURKEY

    Oct 1, 2018, 00:00

  • PND48 - HEALTH AND ECONOMIC BURDEN OF PARKINSON’S DISEASE IN FINLAND

    Oct 1, 2018, 00:00

  • PRM222 - STUDY OF THE SEVERITY OF VASO-OCCLUSIVE CRISIS FOR PATIENT SUFFERING FROM SICKLE CELL DISEASE IN FRANCE USING A MACHINE LEARNING APPROACH ON THE FRENCH MEDICAL INFORMATION SYSTEM DATABASE

    Oct 1, 2018, 00:00

  • PCN337 - HR+/HER2− ADVANCED BREAST CANCER TREATMENT, DISEASE PROGRESSION, AND SURVIVAL IN ARGENTINA, BRAZIL, CHILE, COLOMBIA, AND MEXICO

    Oct 1, 2018, 00:00

  • PCN164 - THE APPLICATION OF A RESPONSE-BASED MODELLING APPROACH WITH A LANDMARK POINT- IMPLICATIONS AND CHALLENGES FOR THE ECONOMIC EVALUATION OF NIVOLUMAB FOR ADVANCED/METASTATIC UROTHELIAL CARCINOMA IN THE UK

    Oct 1, 2018, 00:00

  • PHP320 - ANALYSIS OF HTA PROCESS ON THE BASIS OF PHARMACOECONOMIC GUIDELINES IN CENTRAL EASTERN EUROPEAN COUNTRIES

    Oct 1, 2018, 00:00

  • PCN317 - THE CANCER DRUGS FUND- KEY UNCERTAINTIES, DATA COLLECTION PLANS, ANALYTICAL METHODS AND USE OF THE SYSTEMATIC ANTI-CANCER THERAPY (SACT) REAL WORLD DATA SET

    Oct 1, 2018, 00:00

  • PMD186 - COMPARATIVE ASSESSMENT OF BODY TEMPERATURE MEASURING TECHNIQUES IN FEVERED CHILDREN AT PAEDIATRIC DEPARTMENT

    Oct 1, 2018, 00:00

  • PRS23 - PERSISTENCE TO COPD THERAPIES AND IMPACT ON COSTS RELATED TO HEALTHCARE CONSUMPTION- A FRENCH CLAIMS DATA STUDY

    Oct 1, 2018, 00:00

  • PDB2 - COMPARISON OF ATORVASTATIN AND SIMVASTATIN EFFECT ON GLYCATED HEMOGLOBIN CONTROL AMONG OUTPATIENTS WITH TYPE 2 DIABETES MELLITUS

    Oct 1, 2018, 00:00

  • PRM182 - CULTURAL ADAPTATION AND LOCALISATION OF THE INFLAMMATORY BOWEL DISEASE QUESTIONNAIRE (IBDQ) INTO ARABIC VARIANTS TO ENSURE CULTURAL SUITABILITY.

    Oct 1, 2018, 00:00

  • PRS55 - COST-EFFECTIVENESS OF MEPOLIZUMAB IN SEVERE EOSINOPHILIC ASTHMA PATIENTS IN FRANCE

    Oct 1, 2018, 00:00

  • PMH59 - IDENTIFYING THE ASSOCIATION BETWEEN OUTCOMES AND QUALITY OF LIFE (QOL) OR HEALTH CARE RESOURCE UTILISATION (HCRU) IN SCHIZOPHRENIA- A SYSTEMATIC LITERATURE REVIEW (SLR)

    Oct 1, 2018, 00:00

  • PMS108 - HIGH-FREQUENCY ULTRASOUND EXAMINATION OF LATERAL ANKLE LIGAMENT INJURIES IN CHILDREN

    Oct 1, 2018, 00:00

  • PSS70 - ACNE AND ABSENTEEISM- RESULTS OF A REAL-LIFE STUDY

    Oct 1, 2018, 00:00

  • PCP53 - A DIAGNOSTIC FRAMEWORK TO EVALUATE REAL-WORLD DATA SOURCES FOR REAL-WORLD EVIDENCE GENERATION

    Oct 1, 2018, 00:00

  • PIN101 - ACUTE GASTROENTERITIS HOSPITALIZATIONS- EXPLORING SPATIO-TEMPORAL PATTERNS AND SELF-FINANCED ROTAVIRUS VACCINATION EFFECT

    Oct 1, 2018, 00:00

  • PMH62 - DEPRESCRIBING OF BENZODIAZEPINES AMONGST THE PATIENTS OF DEPARTMENT OF PSYCHIATRY IN A TERTIARY CARE HOSPITAL, BANGALORE, KARNATAKA.

    Oct 1, 2018, 00:00

  • PMD164 - THE MANAGEMENT OF GLYCAEMIC CONTROL IN DIABETIC PATIENTS (T2)- THE ROLE OF GLYCATED ALBUMIN

    Oct 1, 2018, 00:00

  • PCV161 - FOCUS ON LIFE QUALITY IN RECONSTRUCTION VASCULAR SURGERY

    Oct 1, 2018, 00:00

  • PCV30 - REAL WORLD EVIDENCE OF THE RISK OF STROKE OR SYSTEMIC EMBOLISM IN CHRONIC KIDNEY DISEASE PATIENTS WITH ATRIAL FIBRILLATION

    Oct 1, 2018, 00:00

  • PRM167 - MAPPING THE SF-36 TO EQ-5D-3L IN RANDOMIZED TRIAL- THE EMOCAR STUDY (MAY 2011 – APRIL 2016)

    Oct 1, 2018, 00:00

  • PRS71 - WASTEFUL HEALTHCARE SPENDING ON MEDICATION OVERSUPPLY IN ROUTINE USES OF COMBINED INHALED CORTICOSTEROID AND LONG-ACTING BETA2-AGONISTS (ICS/LABA) INHALERS

    Oct 1, 2018, 00:00

  • PMU17 - RETROSPECTIVE STUDY OF PATIENTS USING ELBASVIR/GRAZOPREVIR IN FRANCE

    Oct 1, 2018, 00:00

  • PMH52 - THERAPEUTIC STRATEGIES UTILIZED IN PATIENTS TREATED FOR DEPRESSION IN AN ITALIAN REAL-WORLD SETTING, VENETO REGION.

    Oct 1, 2018, 00:00

  • PCN165 - COST-EFFECTIVENESS OF SORAFENIB FOR METASTATIC RENAL CELL CARCINOMA- A SYSTEMATIC REVIEW

    Oct 1, 2018, 00:00

  • PHP164 - PHARMACEUTICAL POLICIES IN PORTUGAL – TRENDS AND IMPACT

    Oct 1, 2018, 00:00

  • PCV81 - COST-EFFECTIVENESS ANALYSIS OF CLOPIDOGREL VERSUS ASPIRIN FOR HIGH-RISK PATIENTS WITH ESTABLISHED PERIPHERAL ARTERIAL DISEASE IN CHINA

    Oct 1, 2018, 00:00

  • PHP306 - CAN GRADEPRO SUPPORT AND IMPROVE CHOICE OF OUTCOMES IN HEALTH TECHNOLOGY ASSESSMENT? REPORT ON A PILOT USE WITHIN THE EUNETHTA ASSESSMENT OF FEMTOSECOND LASER ASSISTED CATARACT SURGERY (FLACS)

    Oct 1, 2018, 00:00

  • PSY2 - IDENTIFICATION OF POTENTIAL BIAS FROM DATA SOURCES AND STUDY DESIGNS USED TO ESTIMATE PLATELET TRANSFUSION ADVERSE EVENT RATES

    Oct 1, 2018, 00:00

  • PSY140 - DEXMEDETOMIDINE UTILISATION STUDY IN THE INTENSIVE CARE UNIT

    Oct 1, 2018, 00:00

  • CV4 - PATIENT AND CAREGIVER INDIRECT COSTS AFTER ACUTE CARDIOVASCULAR EVENTS IN EUROPE

    Oct 1, 2018, 00:00

  • PDB124 - PERSONALIZED DIABETES MANAGEMENT- WHAT DO PATIENTS WITH DIABETES MELLITUS PREFER?

    Oct 1, 2018, 00:00

  • PIN54 - COST-EFFECTIVENESS OF INTRODUCING MEN VACCINATION AGAINST HUMAN PAPILLOMAVIRUS IN THE CZECH REPUBLIC

    Oct 1, 2018, 00:00

  • PGI35 - ASSESSMENT OF ANTISECRETORY DRUGS CONSUMPTION IN UKRAINE IN COMPARISON WITH OTHER COUNTRIES OF THE WORLD

    Oct 1, 2018, 00:00

  • CE1 - COST-EFFECTIVENESS ANALYSIS OF EMPAGLIFLOZIN IN COMPARISON TO SITAGLIPTIN AND SAXAGLIPTIN BASED ON CARDIOVASCULAR OUTCOME TRIALS

    Oct 1, 2018, 00:00

  • PCN369 - RELATION OF HEALTH RELATED QUALITY OF LIFE WITH INDICATORS OF NUTRITIONAL STATUS IN HEAD AND NECK CANCER PATIENTS ATTENDED IN A MEXICAN THIRD LEVEL PUBLIC FACILITY

    Oct 1, 2018, 00:00

  • PIN113 - ASSESSMENT OF THE EFFICACY AND SAFETY OF ANIDULAFUNGIN, COMPARED WITH OTHER AVAILABLE ANTIFUNGALTHERAPIES TO TREAT INVASIVE CANDIDIASIS- A NETWORK META-ANALYSIS

    Oct 1, 2018, 00:00

  • PCP21 - BIOSIMILARS IN THE UK – A 2018 UPDATE

    Oct 1, 2018, 00:00

  • PRS31 - THE ECONOMIC IMPACT OF OPTIMIZED POST-HOSPITALIZATION MANAGEMENT FOR AN EXACERBATION IN COPD PATIENTS IN CHINA

    Oct 1, 2018, 00:00

  • PHP361 - PIM AND EAMS- THE IMPACT OF PROMISING MEDICINE DESIGNATION IN ACHIEVING PATIENT ACCESS

    Oct 1, 2018, 00:00

  • PIH32 - INNOVATIVE PAYMENT MECHANISM- SOLVING INEQUITIES FOR HER2 (-) BREAST CANCER CASES IN CHILE.

    Oct 1, 2018, 00:00

  • PMU117 - MEASURING IMPROVEMENT IN HEALTH-STATUS WITH THE OXFORD PARTICIPATION AND ACTIVITIES QUESTIONNAIRE

    Oct 1, 2018, 00:00

  • PND38 - ECONOMIC IMPACT OF MULTIPLE SCLEROSIS IN PATIENTS WITH LOW PHYSICAL DISABILITY

    Oct 1, 2018, 00:00

  • PHP311 - UPTAKE OF JOINTLY PRODUCED EUNETHTA HEALTH TECHNOLOGY ASSESSMENTS- WHERE ARE WE NOW?

    Oct 1, 2018, 00:00

  • PDB28 - TYPE 2 DIABETES- CHANGING PATTERNS OF USE OF THE VARIOUS CLASSES OF ANTIDIABETIC DRUGS 8 YEARS AFTER STARTING TREATMENT- A NATIONWIDE COHORT STUDY USING THE FRENCH NATIONAL HEALTH DATA SYSTEM (SNDS)

    Oct 1, 2018, 00:00

  • PIH21 - BUDGET IMPACT OF A NEW INTRAUTERINE SYSTEM IN PORTUGAL

    Oct 1, 2018, 00:00

  • PMD132 - REAL-WORLD ECONOMIC AND CLINICAL OUTCOMES FOR PATIENTS WITH ATRIAL FIBRILLATION UNDERGOING RADIOFREQUENCY ABLATION USING THERMOCOOL® SF CATHETER VERSUS THERMOCOOL® CATHETER

    Oct 1, 2018, 00:00

  • PDB85 - A 10 YEAR COST-EFFECTIVENESS ANALYSIS (CEA) OF THE DIABETES PREVENTION PROGRAM OUTCOMES STUDY (DPP/DPPOS)- CLARIFYING THE PREVIOUS CONFUSION

    Oct 1, 2018, 00:00

  • PND123 - PATIENT AND CAREGIVER WEB-BASED SURVEY- HEALTH UTILITIES IN TUBEROUS SCLEROSIS COMPLEX (TSC) PATIENT POPULATION

    Oct 1, 2018, 00:00

  • PHP78 - PRICING AND REIMBURSEMENT REFORMS IN SPAIN – A SYSTEMATIC ANALYSIS OF NATIONAL PRICING DECISIONS BY THE CIPM

    Oct 1, 2018, 00:00

  • PMD138 - IMPACTS OF NEW EU MDRIVDR REGULATIONS FOR TURKEY

    Oct 1, 2018, 00:00

  • PCN106 - ECONOMIC BURDEN OF END-OF-LIFE AGGRESSION IN LUNG CANCER PATIENTS FROM THE FRENCH HEALTH INSURER PERSPECTIVE

    Oct 1, 2018, 00:00

  • PND64 - COST-EFFECTIVENESS OF CLADRIBINE TABLETS FOR TREATMENT OF RRMS IN THE NETHERLANDS

    Oct 1, 2018, 00:00

  • PMU103 - INCORPORATING PSYCHOLOGICAL CONSTRUCTS INTO PATIENT PREFERENCE STUDIES- WHICH YOU SHOULD CONSIDER INCLUDING IN YOUR NEXT STUDY?

    Oct 1, 2018, 00:00

  • PCN357 - SATISFACTION WITH HEALTH CARE IN LOCALLY ADVANCED HEAD AND NECK CANCER MEXICAN PATIENTS TREATED IN A THIRD LEVEL PUBLIC FACILITY

    Oct 1, 2018, 00:00

  • PCV135 - NON-VITAMIN K ANTAGONIST ORAL ANTICOAGULANTS PRESCRIPTION MONITORING- HOW TO OPTIMIZE VIGILANCE IN STROKE PREVENTION

    Oct 1, 2018, 00:00

  • PSY82 - ANNUAL COST OF CLOTTING FACTORS IN PATIENTS WITH SEVERE (SEV) HEMOPHILIA A (HA) IN FRANCE

    Oct 1, 2018, 00:00

  • PRS66 - ANALYSIS OF INDICATORS OF AVAILABILITY AND CONSUMPTION ANTIHISTAMIN PREPARATIONS IN UKRAINE IN 2017

    Oct 1, 2018, 00:00

  • PRM116 - GENERAL PERCEPTIONS OF INNOVATIVE METHODS FOR SURVIVAL EXTRAPOLATION IN ONCOLOGY AMONG HTA IN EUROPE, CANADA AND AUSTRALIA

    Oct 1, 2018, 00:00

  • PCN121 - BSC COST IN TERMINAL CANCER PATIENTS IN KOREA

    Oct 1, 2018, 00:00

  • PSS24 - ESTIMATION OF THE LONG-TERM POPULATION COSTS AND BENEFITS FOR FIVE DIFFERENT VARICELLA CHILDHOOD IMMUNIZATION STRATEGIES IN BULGARIA

    Oct 1, 2018, 00:00

  • PHP72 - A NEW FRENCH FINANCIAL INCENTIVE TO BOOST INSULIN AND ETANERCEPT BIOSIMILARS PRESCRIBING- SIMULATION OF ECONOMIC IMPACTS FOR THE PUBLIC HOSPITALS OF PARIS

    Oct 1, 2018, 00:00

  • PSY72 - COST OF ILLNESS ANALYSIS- ECONOMIC BURDEN IN DIRECT COSTS OF OBESITY-RELATED CO-MORBIDITIES – STROKE, MYOCARDIAL INFARCTION, TYPE 2 DIABETES - IN RUSSIA

    Oct 1, 2018, 00:00

  • PSY60 - ORPHAN VERSUS ULTRA-ORPHAN DRUGS PRICES IN ENGLAND

    Oct 1, 2018, 00:00

  • PCP26 - THE EUNETHTA COMPANION GUIDE – A REPOSITORY TO STRENGTHEN THE QUALITY OF EUNETHTA’S JOINT HTA PRODUCTION

    Oct 1, 2018, 00:00

  • PCV32 - TRENDS IN THE INPATIENT CARE OF CORONARY HEART DISEASE IN 2005-2015

    Oct 1, 2018, 00:00

  • PCV80 - COST-EFFECTIVENESS OF NOACS IN PREVENTION OF STROKE AND SYSTEMIC EMBOLISM IN THE CZECH REPUBLIC

    Oct 1, 2018, 00:00

  • PHP213 - A RETROSPECTIVE REVIEW OF REIMBURSEMENT DECISIONS BY THE HAUTE AUTORITÉ DE SANTÉ IN 2017 - UNDERLYING RATIONALE FOR MEDICINAL PRODUCTS WITH INSUFFICIENT ACTUAL MEDICAL BENEFIT

    Oct 1, 2018, 00:00

  • PHP167 - COUNTRY-LEVEL COST-EFFECTIVENESS THRESHOLD- INITIAL ESTIMATES IN REPUBLIC OF BELARUS

    Oct 1, 2018, 00:00

  • PHP359 - IMPACT OF EXPEDITED MARKETING AUTHORISATION ON PRICING AND REIMBURSEMENT OUTCOMES FOR DRUGS IN THE US AND EU-5

    Oct 1, 2018, 00:00

  • PMD39 - BUDGET IMPACT ANALYSIS TO TAKE DECISIONS ABOUT TIME OF INVESTMENT RECOVERY IN IMPLANTABLE MEDICAL DEVICES- TRABECULAR MICRO-BYPASS STENT IN OPEN-ANGLE GLAUCOMA

    Oct 1, 2018, 00:00

  • PCN211 - PATIENT CASE-MIX OF A TERTIARY CLINICAL CENTRE WITH PATIENTS DIAGNOSED WITH MALIGNANT MELANOMA BETWEEN 2012-2015

    Oct 1, 2018, 00:00

  • PMS28 - SECUKINUMAB VERSUS INFLIXIMAB IN THE TREATMENT OF PSORIATIC ARTHRITIS- A COST PER RESPONDER ANALYSIS AMONG 48 WEEKS FROM A TUNISIAN PERSPECTIVE.

    Oct 1, 2018, 00:00

  • PSY17 - TREATMENT REGIMENS FOR PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA WHO ARE INELIGIBLE FOR STEM CELL TRANSPLANTATION- A SYSTEMATIC LITERATURE REVIEW AND NETWORK META-ANALYSIS

    Oct 1, 2018, 00:00

  • PMU25 - EXAMINING THE CONSISTENCY AND ACCURACY OF THE BUDGET IMPACT MODELS SUBMITTED TO THE NATIONAL CENTRE FOR PHARMACOECONOMICS IN IRELAND TO AID THE CREATION OF AN APPLICANT TEMPLATE

    Oct 1, 2018, 00:00

  • PND93 - THE IMPACT OF MYASTHENIA GRAVIS (MG) ON HEALTHCARE RESOURCE UTILIZATION- EMPIRICAL EVIDENCE FROM A US REGISTRY SAMPLE

    Oct 1, 2018, 00:00

  • PCN148 - COST-EFFECTIVENESS ANALYSIS OF ATEZOLIZUMAB COMPARED TO TREATMENT OPTIONS FOR ADULT PATIENTS WITH LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) AFTER PRIOR CHEMOTHERAPY - UPDATED RESULTS

    Oct 1, 2018, 00:00

  • PCN380 - THE PROGNOSTIC SIGNIFICANCE OF HEALTH-RELATED QUALITY OF LIFE FROM CANCER RANDOMIZED CONTROLLED TRIALS- A SYSTEMATIC EVALUATION OF THE STATISTICAL METHODS

    Oct 1, 2018, 00:00

  • PUK11 - ECONOMIC BURDEN OF CHRONIC KIDNEY DISEASE RELATED COMPLICATIONS AND THERAPIES IN CHINA- QUANTIFYING THE COSTS OF CARDIOVASCULAR EVENTS, BLOOD TRANSFUSION FOR ANEMIA AND DIALYSIS

    Oct 1, 2018, 00:00

  • PRM92 - INITIAL DEVELOPMENT OF INTELLIGENCE ON HEALTH CARE DATA IN BRASIL- FACING THE OBSTACLES

    Oct 1, 2018, 00:00

  • PND32 - COST COMPARISON OF MULTIPLE SCLEROSIS FIRST LINE TREATMENT WITH AVAILABLE INTERFERONS WITHIN THE BRAZILIAN PUBLIC HEALTHCARE SYSTEM

    Oct 1, 2018, 00:00

  • PHP224 - TEMPORARY ACCESS STRUCTURES FOR INNOVATIVE, HIGH-VALUE THERAPIES- COMPARISON OF MODELS AND CONSEQUENT REIMBURSEMENT TIMELINES

    Oct 1, 2018, 00:00

  • PMU90 - HEALTH PROBLEMS IN HUNGARIAN ELDERLY OUTPATIENTS MEASURED BY THE EQ-5D-3L- COMPARISON WITH A POPULATION NORM FOR CENTRAL EASTERN EUROPE

    Oct 1, 2018, 00:00

  • PND19 - INCIDENCE OF EPILEPSY AFTER STROKES AND REAL-WORLD ANTIEPILEPTIC DRUG TREATMENT

    Oct 1, 2018, 00:00

  • PSY120 - ECONOMIC BURDEN OF SYMPTOMATIC MULTIPLE MYELOMA ON THE ITALIAN HEALTH CARE SYSTEM- FOCUS ON THE MAIN DRIVER COSTS.

    Oct 1, 2018, 00:00

  • PMD44 - COST COMPARISON OF RECHARGEABLE AND NON-RECHARGEABLE DEEP BRAIN STIMULATION DEVICES IN THE NORDIC COUNTRIES

    Oct 1, 2018, 00:00

  • PRM137 - MODELING THE DISTRIBUTION OF TBEV-INFECTED TICKS IN GERMANY TO ESTIMATE TBE-INFECTIONS IN HUMANS

    Oct 1, 2018, 00:00

  • PRM76 - WHAT PHYSICIANS WANT- SEARCH AND EVIDENCE SOURCE TRENDS IN THE TRIP HEALTHCARE DATABASE

    Oct 1, 2018, 00:00

  • PRM103 - SECONDARY USE OF EXISTING PERSONAL HEALTH DATA FOR NON-INTERVENTIONAL STUDIES IN FRANCE

    Oct 1, 2018, 00:00

  • PCN220 - END-OF-LIFE CARE IN PATIENTS WITH METASTATIC CUTANEOUS MELANOMA IN THE NETHERLANDS

    Oct 1, 2018, 00:00

  • PSY204 - EARLY ENGAGEMENT OF THE “PATIENT VOICE” TO INFORM PATIENT REPORTED OUTCOME (PRO) MEASUREMENT IN GLOBAL PIVOTAL TREATMENT TRIAL OF CHOLANGIOCARCINOMA (CCA)

    Oct 1, 2018, 00:00

  • PGI41 - CLINICAL CHARACTERISTICS OF BIOLOGIC TREATED CROHN’S DISEASE PATIENTS WITH AND WITHOUT PRIOR SURGERY IN EUROPEAN UNION

    Oct 1, 2018, 00:00

  • PMU50 - COSTS OF NEUROMONITORING - EXAMINING THE POST-OPERATIVE FINANCIAL BURDEN TO PATIENTS FOLLOWING SPINAL SURGERY

    Oct 1, 2018, 00:00

  • PCN202 - IMPACT OF COMORBID DEPRESSION ON RATES, COSTS, AND HEALTH CARE RESOURCE USE IN BREAST CANCER PATIENTS

    Oct 1, 2018, 00:00

  • PND14 - LONG-TERM EFFECTIVENESS AND CARDIOVASCULAR SAFETY OF ANTIDEMENTIA THERAPIES IN MEDICARE BENEFICIARIES NEWLY DIAGNOSED WITH ALZHEIMER’S DISEASE

    Oct 1, 2018, 00:00

  • PMS98 - EFFECTIVENESS OF FALL PREVENTION PROGRAM IN PATIENTS WITH OSTEOPOROSIS

    Oct 1, 2018, 00:00

  • PHP33 - UNDERSTANDING THE JAPANESE POLICY INITIATIVES AND THE PATIENT CHARACTERISTICS OF RARE, INTRACTABLE DISEASES

    Oct 1, 2018, 00:00

  • PSY28 - EPIDEMIOLOGY OF RPE65 GENE MUTATION RELATED INHERITED RETINAL DYSTROPHIES- A SYSTEMATIC LITERATURE REVIEW

    Oct 1, 2018, 00:00

  • PCN215 - EMERGING TRENDS IN THE MANAGEMENT OF NSCLC PD-L1+ PATIENTS IN ITALY

    Oct 1, 2018, 00:00

  • PHP84 - INVESTIGATING USAGE OF REFERENCE COUNTRIES FOR PRICING AND HEALTH TECHNOLOGY ASSESSMENT OF MEDICINES IN CEE COUNTRIES

    Oct 1, 2018, 00:00

  • PSY39 - QUANTIFYING WORLDWIDE EVIDENCE TO ESTIMATE THE RISK OF TRANSMITTING CREUTZFELDT-JAKOB DISEASE VIA SURGICAL PROCEDURES

    Oct 1, 2018, 00:00

  • PRM123 - AN OVERVIEW OF OPEN-SOURCE MODELS IN HEALTH ECONOMICS

    Oct 1, 2018, 00:00

  • PSS44 - AN EVALUATION OF THE CURRENT TREATMENT PATHWAYS AND ASSOCIATED NHS RESOURCE USE FOR THE MANAGEMENT OF UNCONTROLLED MODERATE-TO-SEVERE ATOPIC DERMATITIS IN SECONDARY CARE

    Oct 1, 2018, 00:00

  • PCN102 - EXTRA-COST OF BRAIN METASTASES IN PATIENTS WITH NON-SQUAMOUS NON-SMALL CELL LUNG CANCER (NSCLC) - A FRENCH NATIONAL HOSPITAL DATABASE ANALYSIS

    Oct 1, 2018, 00:00

  • PDB20 - PERSISTENCE TO LIRAGLUTIDE THERAPY IS ASSOCIATED WITH BETTER GLYCEMIC AND WEIGHT CONTROL IN PATIENTS WITH TYPE 2 DIABETES

    Oct 1, 2018, 00:00

  • PRM253 - EXPLORATION OF NETOWRK META-REGRESSION MODELS APPLIED TO COMPLEX EVIDENCE NETWORKS

    Oct 1, 2018, 00:00

  • PCN71 - BUDGET IMPACT ANALYSIS OF INOTUZUMAB OZOGAMICIN FOR THE TREATMENT OF ADULTS WITH RELAPSED OR REFRACTORY B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA IN BULGARIA

    Oct 1, 2018, 00:00

  • PMS11 - ESTIMATING THE PREVALENCE, AND DESCRIBING THE MEDICAL HISTORY AND TREATMENT PATTERNS OF PATIENTS WITH NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS IN GERMANY – AN APPROACH USING A CLAIMS DATABASE

    Oct 1, 2018, 00:00

  • PMD63 - POTENTIAL LONG-TERM SAVINGS RESULTED FROM THE INTRODUCTION OF INVASIVE EEG MONITORING AS A PREOPERATIVE DIAGNOSTIC PROCEDURE IN EPILEPSY SURGERY IN HUNGARY

    Oct 1, 2018, 00:00

  • PRM198 - STANDARD ERROR OF MEASUREMENT AND SMALLEST DETECTABLE CHANGE OF THE SARQOL® QUESTIONNAIRE- AN ANALYSIS OF SUBJECTS FROM 8 VALIDATION STUDIES

    Oct 1, 2018, 00:00

  • PND95 - THE ECONOMIC BURDEN OF NERVE RELATED INJURIES IN SPINAL CLAIMS IN THE UK

    Oct 1, 2018, 00:00

  • PHP140 - CURRENT CHALLENGES AND POTENTIAL SOLUTION FOR PRICING REGULATORY AND REIMBURSEMENT FRAMEWORK OF INNOVATIVE DRUGS IN EGYPT

    Oct 1, 2018, 00:00

  • PIN122 - INVESTIGATION OF FACILITATING FACTORS OF PARENTS’ DECISION-MAKING IN VACCINATION

    Oct 1, 2018, 00:00

  • PDB44 - THE HEALTH ECONOMIC VALUE OF SHORT-TERM CARDIOVASCULAR BENEFITS ASSOCIATED WITH SGLT-2I FROM CVD-REAL

    Oct 1, 2018, 00:00

  • PND88 - DESCRIBING REAL WORLD TREATMENT PATTERNS IN PAEDIATRIC DRAVET SYNDROME PATIENTS IN DENMARK USING ELECTRONIC MEDICAL RECORDS

    Oct 1, 2018, 00:00

  • PIN112 - HEALTH TECHNOLOGY ASSESSMENT OF THE AVAILABLE NRTI BACKBONES IN ITALY

    Oct 1, 2018, 00:00

  • PDB72 - PLATELET-RICH PLASMA IN DIABETIC FOOT ULCERS- COST-EFFECTIVENESS ANALYSIS FOR SPAIN

    Oct 1, 2018, 00:00

  • PMD102 - COST-EFFECTIVENESS OF USING [18F]FLUTEMETAMOL IN THE CLINICAL EVALUATION OF PATIENTS WITH MILD COGNITIVE IMPAIRMENT OR SUSPECTED DEMENTIA IN SPAIN

    Oct 1, 2018, 00:00

  • PSY57 - A COMPARISON BETWEEN ON DEMAND USAGE OF RFVIIA VS PROPHYLAXIS USE OF EMICIZUMAB IN HIGH TITER INHIBITORY HEMOPHILIA A PATIENTS IN IRAN; A COST UTILITY ANALYSIS

    Oct 1, 2018, 00:00

  • PSY151 - REAL-WORLD IMPACT OF HIGH CONCENTRATION NON-AVIAN HIGH MOLECULAR WEIGHT HYALURONAN ON UTILIZATION PATTERNS OF PAIN MEDICATIONS AMONG PATIENTS WITH OSTEOARTHRITIS OF KNEE

    Oct 1, 2018, 00:00

  • PCV100 - ANALYSIS OF DEMOGRAPHY DATA OF PATIENTS REGISTERED WITH ACUTE MYOCARDIAL INFARCTION ACCORDING TO TYPE OF INSTITUTE IN HUNGARY

    Oct 1, 2018, 00:00

  • PND47 - ECONOMIC BURDEN OF ALZHEIMER’S DISEASE IN THE UK

    Oct 1, 2018, 00:00

  • PRM60 - THE BURDEN OF OSTEOPOROSIS IN FOUR LATIN AMERICAN COUNTRIES- BRAZIL, MEXICO, COLOMBIA, AND ARGENTINA.

    Oct 1, 2018, 00:00

  • PCV33 - THE RATE OF CARDIOVASCULAR EVENTS IN DIABETIC PATIENTS IN COLOMBIA

    Oct 1, 2018, 00:00

  • PMD62 - ADVANCEMENT IN SELF-MONITORING OF BLOOD GLUCOSE (SMBG) TECHNOLOGY IMPROVES METABOLIC CONTROL, DIABETES MANAGEMENT AND PATIENT SATISFACTION IN PATIENTS WITH DIABETES AND HAS THE POTENTIAL FOR SUBSTANTIAL COST SAVINGS FOR THE GERMAN H ...

    Oct 1, 2018, 00:00

  • PRM262 - TRENDS IN DRUG PRICES BEFORE AND AFTER GENERIC COMPETITION IN THE US (2014-2016)

    Oct 1, 2018, 00:00

  • PHP279 - ASSESSMENT OF THE NICE FAST-TRACK APPRAISAL (FTA) PROCESS

    Oct 1, 2018, 00:00

  • PHP227 - THE CURRENT REIMBURSEMENT LANDSCAPE FOR DIGITAL HEALTH IN THE UK- HOW FAR ARE WE FROM A CENTRALISED, NATIONAL SYSTEM?

    Oct 1, 2018, 00:00

  • PSY133 - LIVES SAVED FROM REDUCTIONS IN CO-PRESCRIBING OF OPIOIDS AND BENZODIAZEPINES

    Oct 1, 2018, 00:00

  • PGI34 - A COST SAVING MEASURE FROM THE UTILISATION OF BIOSIMILAR INFLIXIMAB IN THE IRISH SECONDARY CARE SETTING

    Oct 1, 2018, 00:00

  • PSY16 - HEALTH OUTCOME IMPROVEMENTS IN SPINAL MUSCULAR ATROPHY TYPE 1 PATIENTS WITH AVXS-101 GENE REPLACEMENT THERAPY

    Oct 1, 2018, 00:00

  • PMU43 - THE COST OF INFORMAL CARE IN HUNGARY- A POOLED ANALYSIS OF 14 CROSS-SECTIONAL STUDIES

    Oct 1, 2018, 00:00

  • PSY52 - ECONOMIC IMPACT OF IMPROVING PATIENT SAFETY USING SUGAMMADEX FOR ROUTINE REVERSAL OF NEUROMUSCULAR BLOCKADE IN SPAIN

    Oct 1, 2018, 00:00

  • PCN10 - ECONOMIC IMPACT OF MEDICATION ERRORS DETECTED IN ONCOLOGIC INPATIENTS AND OUTPATIENTS IN A MEXICAN HOSPITAL

    Oct 1, 2018, 00:00

  • PHP218 - HOW HIGH CAN YOU GO? - THE IMPACT OF INDICATION EXPANSION AND MARKET COMPETITION ON DRUG PRICES IN THE EU5

    Oct 1, 2018, 00:00

  • PHP276 - A REVIEW OF THE IMPACT OF INTEGRATED SCIENTIFIC ADVICE FOR THE OPTIMISATION OF EVIDENCE GENERATION FOR HTA APPRAISALS

    Oct 1, 2018, 00:00

  • PHP111 - EXPLORING THE LEVELS OF UNDERSTANDING OF PERSONALIZED MEDICINE AMONGST MEDICAL STUDENTS IN SARAJEVO

    Oct 1, 2018, 00:00

  • PSY135 - ACCESS TO ORPHAN DRUGS – REGULATION WITHIN THE EUROPEAN LAW

    Oct 1, 2018, 00:00

  • PCN157 - COST-EFFECTIVENESS ANALYSIS OF THE USE OF COLONOSCOPY AS A SCREENING METHOD FOR COLON CANCER IN PATIENTS OVER 50 YEARS OF AGE ON MANDATORY HEALTH INSURANCE

    Oct 1, 2018, 00:00

  • PIN16 - BUDGET IMPACT ANALYSIS OF INTRODUCING A READY-TO-USE, FULLY-LIQUID, PAEDIATRIC, HEXAVALENT VACCINE FOR CHILDHOOD IMMUNISATION IN THE UNITED KINGDOM

    Oct 1, 2018, 00:00

  • PCV145 - A SYSTEMATIC LITERATURE REVIEW (SLR) ON HEALTH STATE UTILITIES ASSOCIATED WITH ANGINA AND REVASCULARISATION

    Oct 1, 2018, 00:00

  • PRS93 - THE HEALTH-RELATED QUALITY OF LIFE BURDEN OF PEANUT ALLERGY IN ADULTS, ADOLESCENTS AND CHILDREN IN THE UK

    Oct 1, 2018, 00:00

  • PCV42 - A PHARMACOECONOMIC ANALYSIS OF THE USE OF APIXABAN FOR THE PREVENTION OF STROKE AND SYSTEMIC EMBOLISM IN RUSSIAN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION

    Oct 1, 2018, 00:00

  • PSY146 - SERIOUS ADVERSE REACTIONS REPORTED FOR DRUGS INVOLVED IN LAWSUITS FILED AGAINST THE BRAZILIAN PUBLIC HEALTH SYSTEM

    Oct 1, 2018, 00:00

  • PSY48 - BUDGET IMPACT ANALYSIS OF LOW-DOSE METHOXYFLURANE FOR THE TREATMENT OF MODERATE-TO-SEVERE TRAUMA PAIN IN CONSCIOUS ADULT PATIENTS IN SPAIN

    Oct 1, 2018, 00:00

  • PRM26 - TIME TO DETERIORATION (TTD) IN HEALTH RELATED QUALITY OF LIFE (HRQOL) IN NSCLC PATIENTS- A REVIEW OF DEFINITIONS

    Oct 1, 2018, 00:00

  • PHP191 - EVALUATION OF THE RENEWED LIFE REFORM PROGRAM FOR WORKERS WITH PREMORBID METABOLIC SYNDROME, OVERWEIGHT AND OBESITY IN THE AMAZONAS ASSISTANCE NETWORK OF PERUVIAN SOCIAL SECURITY

    Oct 1, 2018, 00:00

  • PND53 - MODEL-BASED ECONOMIC EVALUATIONS OF TREATMENTS FOR PARKINSON’S DISEASE- A SYSTEMATIC LITERATURE REVIEW

    Oct 1, 2018, 00:00

  • PHP8 - THE ROLE OF GENERAL PRACTITIONERS IN TRAUMA CARE- VARIATION BY INJURY TYPE, REGION, PATIENT PROFILE, AND OVER TIME

    Oct 1, 2018, 00:00

  • PMD116 - UTILISATION AND ECONOMIC BURDEN OF FLOWABLE HEMOSTATIC AGENTS IN GERMAN HOSPITALS- A REAL-WORLD PATIENT CHART REVIEW STUDY

    Oct 1, 2018, 00:00

  • PSY183 - SCOPE REVIEW OF ORPHAN DRUG PUBLIC POLICIES AND LEGISLATION IN LATIN AMERICA

    Oct 1, 2018, 00:00

  • PRM120 - GRAPHICAL USER-FRIENDLY INTERFACE FOR COMPLEX HEALTH ECONOMIC MODELS BUILT IN R

    Oct 1, 2018, 00:00

  • PMU94 - DEVELOPMENT OF JAPANESE PREFERENCE WEIGHT FOR THE ADULT SOCIAL CARE OUTCOMES TOOLKIT (ASCOT) SCT4

    Oct 1, 2018, 00:00

  • PRS79 - MODELING THE POPULATION YEARS OF LIFE SAVED BY INTRODUCING A REDUCED-RISK PRODUCT IN THE U.S. AND IN JAPAN

    Oct 1, 2018, 00:00

  • PRS76 - DISEASE ADAPTATION AND PERCEIVED HEALTH STATUS- DOES IT EXIST AND CAN IT BE QUANTIFIED? INVESTIGATING EQ-5D IN SEVERE ASTHMA

    Oct 1, 2018, 00:00

  • PCN170 - COST-EFFECTIVENESS OF TISAGENLECLEUCEL IN PEDIATRIC AND YOUNG ADULT PATIENTS WITH RELAPSED OR REFRACTORY B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA- A CANADIAN SOCIETAL PERSPECTIVE

    Oct 1, 2018, 00:00

  • PRM224 - ARE POTENTIALLY AVOIDABLE HOSPITALIZATIONS EXPLAINED BY PRIMARY CARE? BEWARE OF SPATIAL HETEROGENEITY.

    Oct 1, 2018, 00:00

  • PSS19 - IMPORTANCE OF THE OUT-OF-POCKET COST FOR ATOPIC DERMATITIS AFFECTED ADULTS

    Oct 1, 2018, 00:00

  • PRM93 - SNDS, THE FRENCH NATIONWIDE CLAIMS DATABASE- A POWERFUL TOOL FOR PHARMACOECONOMY AND PHARMACOEPIDEMIOLOGY

    Oct 1, 2018, 00:00

  • PRS57 - ECONOMIC EVALUATION OF SINGLE INHALER TRIPLE THERAPY FOR PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) USING THE GALAXY MODEL

    Oct 1, 2018, 00:00

  • PCN349 - CAN WE APPLY THE UTILITY PREDICTION MATHEMATICAL MODEL FOR RECURRENT METASTATIC BREAST CANCER TO JAPANESE PATIENTS?

    Oct 1, 2018, 00:00

  • CN4 - COMPARISON OF MACHINE LEARNING ALGORITHMS FOR THE PREDICTION OF MISSING CROSS-SECTIONAL COST DATA

    Oct 1, 2018, 00:00

  • PRM181 - USE OF ARTIFICIAL INTELLIGENCE WITH DISTILLERSR SOFTWARE FOR A SYSTEMATIC LITERATURE REVIEW OF UTILITIES IN INFECTIOUS DISEASE

    Oct 1, 2018, 00:00

  • PHP295 - REVIEW OF POSSIBLE CAUSES OF VARIATION IN NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE (NICE) TECHNOLOGY APPRAISALS

    Oct 1, 2018, 00:00

  • PMU47 - THE ECONOMIC BURDEN OF OCCUPATIONAL INJURY AMONG FRONTLINE CONSTRUCTION WORKERS IN GHANA

    Oct 1, 2018, 00:00

  • PHP48 - INTERNATIONAL REFERENCE PRICING OF PHARMACEUTICALS- APPLY LIBERALLY OR USE SPARINGLY?

    Oct 1, 2018, 00:00

  • PMS92 - THE CORRELATION BETWEEN MENTAL DISORDER PARAMETERS AND MEDICAL ADHERENCE IN PATIENTS WITH RHEUMATOID ARTHRITIS

    Oct 1, 2018, 00:00

  • PMD95 - ECONOMIC EVALUATION OF STRATEGIES WITH/WITHOUT P16 FOR OPPORTUNISTIC CERVICAL CANCER SCREENING

    Oct 1, 2018, 00:00

  • PMD112 - COST-UTILITY ANALYSIS OF VAGUS NERVE STIMULATION(VNS) FOR CHILDREN WITH INTRACTABLE EPILEPSY IN TAIWAN

    Oct 1, 2018, 00:00

  • PRS52 - COST-MINIMIZATION ANALYSIS OF SQ® HDM SLIT-TABLET IN PATIENTS WITH HOUSE DUST MITE ALLERGIC RHINITIS WITH OR WITHOUT ALLERGIC ASTHMA IN POLAND

    Oct 1, 2018, 00:00

  • HT2 - PATIENT CENTRIC MEASURES IN HTAS FOR AUTOIMMUNE DISEASES

    Oct 1, 2018, 00:00

  • PMD161 - CLINICAL IMPACT OF A PHARMACEUTICAL PROFESIONAL SERVICE INTERVENTION WITH OR WITHOUT A MULTI-COMPARTMENT MEDICATION IN NON-ADHERENT, UNCONTROLLED, CHRONIC HYPERTENSIVE, POLYMEDICATED PATIENTS IN SPANISH COMMUNITY PHARMACIES. SEFAC- ...

    Oct 1, 2018, 00:00

  • PSS25 - COST-EFFECTIVENESS ANALYSIS OF INTRAVITREAL AFLIBERCEPT VERSUS RANIBIZUMAB IN THE TREATMENT OF DIABETIC MACULAR EDEMA (DME) UNDER THE BRAZILIAN PUBLIC HEALTHCARE SYSTEM (SUS)

    Oct 1, 2018, 00:00

  • PRM163 - AN APPROACH TO EVALUATING THE EFFECT OF PRIORS IN NETWORK META-ANALYSIS

    Oct 1, 2018, 00:00

  • PSY170 - IMPACT OF MULTIPLE INDICATIONS ON PRICE AND ACCESS OF DRUGS FOR AUTOIMMUNE DISEASES

    Oct 1, 2018, 00:00

  • PGI15 - HEALTHCARE RESOURCE UTILIZATION (HCRU) IN METASTATIC OR UNRESECTABLE GASTRIC OR GASTROESOPHAGEAL JUNCTION CANCER PATIENTS RECEIVING SECOND-LINE TREATMENT

    Oct 1, 2018, 00:00

  • PCV156 - CORRELATION OF THE DISEASE-SPECIFIC CSS/NYHA CLASSIFICATION WITH GENERIC HEALTH-RELATED QUALITY OF LIFE IN CORONARY ARTERY DISEASE PATIENTS

    Oct 1, 2018, 00:00

  • PSY98 - COST-EFFECTIVENESS ANALYSIS OF FERRIC MALTOL VERSUS FERRIC CARBOXYMALTOSE FOR THE TREATMENT OF IRON DEFICIENCY ANAEMIA IN IBD PATIENTS IN SWEDEN AND FINLAND

    Oct 1, 2018, 00:00

  • PMH75 - PATIENT-REPORTED OUTCOMES IN PATIENTS WITH DEPRESSION- A QUALITATIVE STUDY

    Oct 1, 2018, 00:00

  • PND11 - INDIRECT TREATMENT COMPARISON OF AVXS-101 TO NUSINERSEN FOR THE TREATMENT OF TYPE 1 SPINAL MUSCULAR ATROPHY

    Oct 1, 2018, 00:00

  • PCV22 - LIPID-LOWERING DRUG PRESCRIPTIONS IN A GROUP OF COLOMBIAN PATIENTS.

    Oct 1, 2018, 00:00

  • PMS66 - IMPROVING PATIENT AND FINANCIAL OUTCOMES IN THE NHS- EARLY ARTHRITIS SERVICE INCREASES PATIENT SATISFACTION WHILST SAVING COSTS

    Oct 1, 2018, 00:00

  • PND135 - FATIGUE IN MULTIPLE SCLEROSIS- ASSESSING THE PSYCHOMETRIC PROPERTIES OF THE MFIS-5 QUESTIONNAIRE

    Oct 1, 2018, 00:00

  • PCV41 - COST IMPACT ANALYSIS OF USING IMPROVE® TOOL FOR VENOUS THROMBOEMBOLISM RISK ASSESSMENT IN MEDICAL PATIENTS ADMITTED TO THE UK NHS HOSPITALS TO INFORM NICE CLINICAL GUIDELINE RECOMMENDATION

    Oct 1, 2018, 00:00

  • PRM273 - METHODOLOGICAL CONSIDERATIONS ON THE RECOMMENDATIONS TO CONDUCT AND REPORT SYSTEMATIC REVIEWS IN MEDICAL LITERATURE- SYSTEMATIC REVIEW

    Oct 1, 2018, 00:00

  • PMD89 - COST-EFFECTIVENESS OF OXIGEN THERAPY WITH C-PAP FOR THE TREATMENT OF OBSTRUCTIVE SLEEP APNOEA SYNDROME (OSA) VERSUS THE STANDARD OF CARE IN THE MEXICAN PUBLIC HEALTH CARE SYSTEM

    Oct 1, 2018, 00:00

  • PMU118 - COGNITIVE DEBRIEFING INTERVIEW STUDIES TO INFORM PATIENT-REPORTED OUTCOME QUESTIONNAIRE DEVELOPMENT- A LITERATURE REVIEW AND SUGGESTED REPORTING GUIDELINES

    Oct 1, 2018, 00:00

  • PRM204 - PSYCHOMETRIC EVALUATION OF EORTC QLQ-C30 IN CUBAN PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER

    Oct 1, 2018, 00:00

  • PSS30 - COST EFFECTIVENESS OF DIMETHYL FUMARATE (DMF) IN THE TREATMENT OF MODERATE TO SEVERE PLAQUE PSORIASIS- A UK PERSPECTIVE

    Oct 1, 2018, 00:00

  • PRM261 - INCORPORATION OF OBSERVATIONAL DATA INTO NETWORK META-ANALYSIS- A CASE STUDY

    Oct 1, 2018, 00:00

  • PP3 - TUNING INTO WHAT PATIENTS SAY ABOUT CLINICAL TRIALS WHEN SCIENTISTS AND CLINICIANS ARE NOT LISTENING- IMPLICATIONS FOR RECRUITMENT

    Oct 1, 2018, 00:00

  • PIN23 - CLINICAL AND ECONOMIC BURDEN OF INVASIVE MENINGOCOCCAL DISEASE IN FRANCE

    Oct 1, 2018, 00:00

  • PIH47 - SELF-MEDICATION PRACTICE IN PRIMARY DYSMENORRHEA AMONG MEDICAL AND PHARMACY STUDENTS IN UNAIZAH – KSA - A CROSS-SECTIONAL QUESTIONNAIRE STUDY

    Oct 1, 2018, 00:00

  • PHP177 - THE USAGE OF PACKAGE CRITERIA IN DUTCH REIMBURSEMENT DECISION MAKING AND THEIR INFLUENCE ON ZIN RECOMMENDATIONS

    Oct 1, 2018, 00:00

  • PHP142 - SEVERITY ADJUSTED PROBABILITY OF BEING COST-EFFECTIVE- A NOVEL APPROACH TO INTEGRATE SEVERITY AND COST-EFFECTIVENESS WITH APPLICATIONS TO NORWAY AND THE NETHERLANDS

    Oct 1, 2018, 00:00

  • PCP34 - BIOSIMILARS- WHAT’S THE ISSUE?

    Oct 1, 2018, 00:00

  • PDB40 - IMPACT OF DAPAGLIFLOZIN ON REDUCING ECONOMIC BURDEN OF TYPE 2 DIABETES ENHANCEMENT PATIENT’S OUTCOMES AT COUNTRIES WITH HIGH INCIDENCE OF DIABETES EGYPT CASE

    Oct 1, 2018, 00:00

  • PRS82 - TREND AND FACTORS ASSOCIATED WITH PREVENTABLE HOSPITALIZATION AMONG CHRONIC OBSTRUCTIVE PULMONARY DISEASE PATIENTS- A DECADE EXPERIENCE OF A NATIONAL HEALTH INSURANCE PROGRAM

    Oct 1, 2018, 00:00

  • PHP99 - OVER-THE-COUNTER MEDICINES USE AND ITS ASSOCIATION WITH RISK PERCEPTION AND SAFETY AMONG WOMEN VISITING COMMUNITY PHARMACIES IN MALAYSIA

    Oct 1, 2018, 00:00

  • PCN291 - MARKET ACCESS FOR ONCO-HEMATOLOGY MEDICINES - VALUE OF SINGLE ARM STUDIES - ANALYSIS OF FRENCH HTA OPINIONS

    Oct 1, 2018, 00:00

  • PCV88 - PHARMACOECONOMICS OF ALIROCUMAB IN TREATMENT OF HYPERCHOLESTEROLEMIA- A SYSTEMATIC REVIEW

    Oct 1, 2018, 00:00

  • PCN63 - REVIEW OF NICE HTA SUBMISSIONS INCLUDING MATCHING-ADJUSTED INDIRECT COMPARISONS AND SIMULATED TREATMENT COMPARISONS

    Oct 1, 2018, 00:00

  • PHP147 - CHANGES IN THE NUMBER OF PHYSICIANS IN THE HEALTH CARE SYSTEM OF EUROPEAN COUNTRIES

    Oct 1, 2018, 00:00

  • PRM272 - THE EUNETHTA TRANSFERABILITY TOOL- APPLICATION TO NOVEL TREATMENTS FOR RELAPSED REFRACTORY MULTIPLE MYELOMA IN THE IRISH HEALTHCARE SETTING

    Oct 1, 2018, 00:00

  • PIN73 - ECONOMIC BURDEN OF HIV/AIDS AMONG ELDERLY MEDICARE BENEFICIARIES POST MEDICARE PART D

    Oct 1, 2018, 00:00

  • PGI13 - REAL-LIFE BUDGET IMPACT OF DIRECT-ACTING ANTIVIRALS AGAINST HEPATITIS C VIRUS IN AN SPANISH PUBLIC HOSPITAL PHARMACY

    Oct 1, 2018, 00:00

  • PIN14 - BIOMEDICAL AND THERAPEUTIC PREDICTORS OF SURVIVAL TIME AND MORTALITY OF ADULT HIV/TB CO-INFECTIONS; A RETROSPECTIVE COHORT STUDY

    Oct 1, 2018, 00:00

  • PCN58 - MEDIAN SURVIVAL, MEAN SURVIVAL OR HAZARD RATIO- WHICH ENDPOINT IS THE MOST APPROPRIATE FOR PATIENTS, PHYSICIANS AND POLICY MAKERS?

    Oct 1, 2018, 00:00

  • PMU74 - POTENTIAL COST SAVINGS BY PREVENTION OF ADVERSE DRUG EVENTS WITH A NOVEL MEDICATION REVIEW PROGRAM

    Oct 1, 2018, 00:00

  • PHP204 - VALIDATION OF A MULTICRITERIA DECISION ANALYSIS (MCDA) FRAMEWORK TO INCORPORATE THE PATIENTS’ PERSPECTIVE IN HEALTH TECHNOLOGY ASSESSMENT

    Oct 1, 2018, 00:00

  • PMS4 - RHEUMATOID ARTHRITIS TREATED WITH SIX-MONTHS OF FIRST-LINE BIOLOGIC OR BIOSIMILAR THERAPY- A SYSTEMATIC REVIEW AND NETWORK META-ANALYSIS

    Oct 1, 2018, 00:00

  • PHP2 - CHARACTERISTICS OF DOCTOR-SHOPPERS- A SYSTEMATIC LITERATURE REVIEW

    Oct 1, 2018, 00:00

  • PMH63 - ACCESS TO ANTI-DEPRESSANT THERAPIES IN ENGLAND- IS THERE A POSTCODE LOTTERY?

    Oct 1, 2018, 00:00

  • PMS73 - BRIGHT FUTURE FOR THE USE OF BIOSIMILAR INFLIXIMAB- EVIDENCE-BASED ANALYSIS USING HEALTHCARE CLAIM DATABASE

    Oct 1, 2018, 00:00

  • PHP369 - CHALLENGES IN ACHIEVING MARKET ACCESS SUCCESS FOR ADVANCED THERAPIES IN EUROPE- A CASE STUDY

    Oct 1, 2018, 00:00

  • PCN251 - DESCRIPTIVE ANALYSIS OF THE USE OF TYROSINE KINASE INHIBITORS IN CHRONIC MYELOID LEUKAEMIA IN EUROPE, A REAL-WORLD PERSPECTIVE

    Oct 1, 2018, 00:00

  • PDB22 - CLINICAL AND DEMOGRAPHIC CHARACTERISTICS OF PATIENTS REACHING A HIGH DAILY DOSE OF IDEGLIRA SIX MONTHS AFTER INITIATION IN A REAL-WORLD SETTING

    Oct 1, 2018, 00:00

  • PCN183 - ROBOTIC VERSUS LAPAROSCOPIC SURGERY FOR RECTAL CANCER- A COMPARATIVE STUDY OF CLINICAL OUTCOMES AND COSTS-EFFECTIVENESS

    Oct 1, 2018, 00:00

  • PHP234 - EVALUATING THE IMPACT OF VALUE BASED PRICING (VBP) AND HTA ON PRICE LEVELS IN AN EU CONTEXT

    Oct 1, 2018, 00:00

  • PCN86 - VALIDATION OF THE IMPACT OF TREATMENT EVOLUTION IN NON-SMALL CELL LUNG CANCER (NSCLC) MODEL (ITEN)- A DISCRETE EVENT PATIENT SIMULATION

    Oct 1, 2018, 00:00

  • PND116 - A THREE MONTH INTERIM ANALYSIS OF FINGOLIMOD TREATMENT ADHERENCE FOR RELAPSING REMITTING MULTIPLE SCLEROSIS IN THE UK- THE PATIENT REPORTED OUTCOMES WITH FINGOLIMOD IN LOCAL EXPERIENCE (PROFILE) STUDY

    Oct 1, 2018, 00:00

  • Association between Higher Generic Drug Use and Medicare Part D Star Ratings- An Observational Analysis

    Oct 1, 2018, 00:00

  • PMH15 - A NETWORK META-ANALYSIS OF MEDICINES USED FOR ATTENTION DEFICIT HYPERACTIVITY DISORDER IN ADULTS

    Oct 1, 2018, 00:00

  • PMU62 - ECONOMIC EVALUATION OF MESALAZINE 4G (SALOFALK®) IN THE TREATMENT OF PATIENTS WITH ULCERATIVE COLITIS LOCATED IN THE RECTUM AND SIGMOID

    Oct 1, 2018, 00:00

  • PRM190 - METHODS USED TO VALUE HEALTH RELATED QUALITY IN A SYSTEMATIC REVIEW OF COST-UTILITY ANALYSES IN HEART FAILURE

    Oct 1, 2018, 00:00

  • PCV51 - COST ANALYSIS OF SAFETY OUTCOMES OF DABIGATRAN VS. WARFARIN IN THE SPANISH NATIONAL HEALTH SERVICE

    Oct 1, 2018, 00:00

  • PCN184 - COST-EFFECTIVENESS OF NIVOLUMAB PLUS IPILIMUMAB IN ADVANCED MELANOMA

    Oct 1, 2018, 00:00

  • PRM185 - COMPARISON OF THE MEASUREMENT PROPERTIES OF THE EQ-5D-5L AND EQ-5D-3L IN PATIENTS WITH CROHN’S DISEASE

    Oct 1, 2018, 00:00

  • PRM8 - CLINICAL APPLICATION AND USAGE OF PATIENT REPORTED OUTCOME MEASURES IN AN ORTHOPAEDIC OUTPATIENT SETTING

    Oct 1, 2018, 00:00

  • PND138 - INFORMATION SEARCHING PREFERENCES IN PEOPLE WITH MULTIPLE SCLEROSIS- THE INFOSEEK STUDY

    Oct 1, 2018, 00:00

  • PCN2 - EFFECTIVENESS AND SAFETY OF PEMBROLIZUMAB IN ADVANCED OR METASTATIC MELANOMA- PRELIMINARY RESULTS FROM REAL WORLD

    Oct 1, 2018, 00:00

  • PMU24 - WHICH MODEL(S) ARE USED TO ASSESS INDIVIDUAL-LEVEL SURROGACY IN ONCOLOGY USING KENDALL’S TAU? A SYSTEMATIC LITERATURE REVIEW

    Oct 1, 2018, 00:00

  • PRM45 - DIRECT DATA WITHOUT DUPLICATION OF EFFORT- EXPERIENCE OF OBTAINING ELECTRONIC ROUTINE RESOURCE USE DATA DIRECTLY FROM HOSPITALS FROM THE UPSTREAM RCT.

    Oct 1, 2018, 00:00

  • PDB80 - RE-ANALYSIS OF THE DIABETES PREVENTION PROGRAM 3 YEAR COST-EFFECTIVENESS ANALYSIS (CEA) USING IDENTICAL DATA BUT PROPER METHODS QUESTIONS ITS CONCLUSIONS

    Oct 1, 2018, 00:00

  • PMS102 - THE RELATION BETWEEN TRAINING METHODS AND FORMED INJURIES AMONG PEOPLE DOING WEIGHT TRAINING

    Oct 1, 2018, 00:00

  • PRM82 - REAL WORLD EVIDENCE (RWE) FROM ITALIAN NHS-AIFA REGISTRIES

    Oct 1, 2018, 00:00

  • PCN185 - COST-EFFECTIVENESS OF NIVOLUMAB IN SECOND-LINE TREATMENT OF LOCALLY ADVANCED UNRESECTABLE OR METASTATIC UROTHELIAL CARCINOMA IN ADULTS AFTER FAILURE OF PRIOR PLATINUM-CONTAINING THERAPY IN GREECE

    Oct 1, 2018, 00:00

  • PCN366 - QUALITATIVE PATIENT INTERVIEWS TO SUPPORT THE FACT HEPATOBILIARY SYMPTOM INDEX-8 AMONG PATIENTS WITH HEPATOCELLULAR CARCINOMA AND ELEVATED BASELINE ALPHA-FETOPROTEIN

    Oct 1, 2018, 00:00

  • PSY164 - DRIVERS OF ORPHAN MEDICINAL PRODUCT VALUE, PRICE AND COSTS – A PRACTICAL EXPLORATORY ANALYSIS

    Oct 1, 2018, 00:00

  • PCV61 - PRODUCTIVITY LOSS AND LOCAL INDIRECT COSTS ASSOCIATED WITH ACUTE CORONARY SYNDROME AND STROKE IN SPAIN

    Oct 1, 2018, 00:00

  • PND62 - COST-EFFECTIVENESS OF CLADRIBINE TABLETS IN THE TREATMENT OF PATIENTS WITH HIGHLY ACTIVE RELAPSING MULTIPLE SCLEROSIS IN PORTUGAL

    Oct 1, 2018, 00:00

  • PUK25 - EVALUATION OF THE RECOMMENDATIONS COMPLIANCE ON THE DIABETIC NEPHROPATHY MANAGEMENT IN FRANCE- THE ND-CRIS COHORT (2012-2017)

    Oct 1, 2018, 00:00

  • PCV86 - COST-EFFECTIVENESS OF SACUBITRIL/VALSARTAN IN THE TREATMENT OF HEART FAILURE UNDER THE BRAZILIAN PRIVATE HEALTHCARE SYSTEM PERSPECTIVE

    Oct 1, 2018, 00:00

  • PHP221 - CONDITIONAL APPROVAL- ARE PAYERS REWARDING THESE HIGHLY NEEDED PHARMACEUTICALS?

    Oct 1, 2018, 00:00

  • PMU116 - PATIENT-REPORTED OUTCOMES IN A PILOT RANDOMIZED TRIAL OF GENOME SEQUENCING

    Oct 1, 2018, 00:00

  • PGI46 - PSYCHOMETRIC EVALUATION OF THE DIARY FOR IRRITABLE BOWEL SYNDROME SYMPTOMS-CONSTIPATION (DIBSS-C)

    Oct 1, 2018, 00:00

  • PSY166 - MARKET ACCESS TRENDS FOR ADVANCED THERAPY MEDICINAL PRODUCTS (ATMPS) IN EUROPE

    Oct 1, 2018, 00:00

  • PDB115 - IS USING MMAS-8 ALONE RELIABLE AND NONBIAS WHEN MEASURING MEDICATION ADHERENCE?

    Oct 1, 2018, 00:00

  • PND40 - COST OF HEALTHCARE RESOURCE USE BY PATIENTS WITH MULTIPLE SCLEROSIS IN FRANCE ACCORDING TO DISEASE SEVERITY

    Oct 1, 2018, 00:00

  • PRM213 - LEARNINGS FROM CONSUMER RESEARCH FOR PATIENT PREFERENCE RESEARCH

    Oct 1, 2018, 00:00

  • PCV109 - ARE CARDIOVASCULAR MEDICINES IN QATAR AND LEBANON AFFORDABLE? AN ANALYSIS AND COMPARISON OF TWO DEVELOPING MIDDLE-EASTERN COUNTRIES

    Oct 1, 2018, 00:00

  • PRS34 - COST AND DRUG UTILIZATION TRENDS IN INHALED CORTICOSTEROIDS/LONG-ACTING BETA AGONISTS (ICS/LABA) FIXED-DOSE COMBINATIONS IN SPAIN

    Oct 1, 2018, 00:00

  • PCN378 - MINIMALLY IMPORTANT DIFFERENCES FOR INTERPRETING EORTC QLQ-C30 SCORES IN MELANOMA, BREAST CANCER AND HEAD AND NECK CANCER PATIENTS ON BEHALF OF THE EORTC BREAST, HEAD AND NECK, MELANOMA AND QUALITY OF LIFE GROUPS

    Oct 1, 2018, 00:00

  • PRM130 - OPEN-SOURCE SOFTWARE FOR DEVELOPING COMPUTATIONALLY EFFICIENT COST-EFFECTIVENESS MODELS TO EVALUATE SEQUENTIAL TREATMENT STRATEGIES IN ONCOLOGY

    Oct 1, 2018, 00:00

  • PHP294 - A REVIEW OF RECENT APPRAISALS FROM THE INSTITUTE FOR CLINICAL AND ECONOMIC REVIEW- HOW IMPORTANT IS THE ICER?

    Oct 1, 2018, 00:00

  • ND4 - COST-EFFECTIVENESS EVALUATION OF THE INTRA-DUODENAL CONTINUOUS LEVODOPA INFUSION IN ADVANCED AND SEVERE PARKINSON’S DISEASE

    Oct 1, 2018, 00:00

  • PIH2 - CLINICAL AND DEMOGRAPHIC RISK FACTORS AND COSTS OF SURGICAL SITE INFECTION FOLLOWING HYSTERECTOMY

    Oct 1, 2018, 00:00

  • PDB54 - ESTIMATED EVENTS AVOIDED AND COST OFFSETS ASSOCIATED WITH USING CANAGLIFLOZIN TO TREAT PATIENTS WITH TYPE TWO DIABETES MELLITUS (T2DM) WITH OR AT HIGH RISK OF DEVELOPING CARDIOVASCULAR DISEASE (CVD) IN ENGLAND

    Oct 1, 2018, 00:00

  • PGI8 - SYSTEMATIC LITERATURE REVIEW AND INDIRECT TREATMENT COMPARISON OF LINACLOTIDE VERSUS OTHER ORAL CONSTIPATION TREATMENTS IN PATIENTS WITH CHRONIC CONSTIPATION

    Oct 1, 2018, 00:00

  • PHP24 - ANALYSIS OF SPANISH THERAPEUTIC POSITIONING REPORTS PUBLISHED UNTIL 2017

    Oct 1, 2018, 00:00

  • PMD131 - MEDICAL IMAGING EQUIPMENT IN ITALY- STATE OF ART OF INSTALLED BASE AND RENEWAL STRATEGIES

    Oct 1, 2018, 00:00

  • PDB105 - INCREASED BURDEN OF MULTIMORBIDITY AMONGST DIABETES PATIENTS- A MULTINATIONAL SURVEY

    Oct 1, 2018, 00:00

  • PSS27 - A COST-EFFECTIVENESS ANALYSIS OF TWO VISUAL ACUITY CUTOFFS FOR CATARACT SURGERY IN PATIENTS WITH PSEUDOEXFOLIATION IN UNITED KINGDOM

    Oct 1, 2018, 00:00

  • PCN158 - THE ADDED VALUE OF PERSONALIZED FOLLOW-UP FOR CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS

    Oct 1, 2018, 00:00

  • PSY167 - COMPARISON OF PHARMACOECONOMIC (PE) EVALUATIONS FOR DRUGS FOR RARE DISEASES (DRDS) EVALUATED BY CADTH AND NICE.

    Oct 1, 2018, 00:00

  • PMD13 - PREVALENCE OF ISOLATED HYPERTENSION AMONG OUTPATIENTS WITH TYPE 2 DIABETES MELLITUS

    Oct 1, 2018, 00:00

  • PCV144 - EFFECT OF CONVENIENCE OF ORAL ANTICOAGULANT THERAPY ON MEDICATION ADHERENCE- RESULTS OF AN INTERNATIONAL STATED PREFERENCE SURVEY

    Oct 1, 2018, 00:00

  • PMS21 - BUDGET IMPACT MODEL OF INCLUSION OF TOFACITINIB FOR THE TREATMENT OF RHEUMATOID ARTHRITIS IN FRANCE

    Oct 1, 2018, 00:00

  • PSY203 - DESCRIPTIVE EPIDEMIOLOGY OF OBESITY IN A REAL WORLD POPULATION OF ADULTS IN THE UNITED STATES- 2010 - 2017

    Oct 1, 2018, 00:00

  • PDB131 - LATENT CLASS ANALYSIS FOR PERSONALIZED DIABETES MANAGEMENT- ONE SIZE DOES NOT FIT ALL?

    Oct 1, 2018, 00:00

  • PSY220 - IMPACT OF KERATOCONUS AND ITS TREATMENTS ON PATIENTS’ DAILY LIFE- QUALITATIVE PHASE OF THE DEVELOPMENT OF A QUALITY OF LIFE QUESTIONNAIRE

    Oct 1, 2018, 00:00

  • PMH76 - PATIENT REPORTED MEASURES OF DEPRESSIVE SYMPTOMS AND FATIGUE IN A PHASE 2, RANDOMIZED, PLACEBO-CONTROLLED TRIAL OF THE GABAA RECEPTOR POSITIVE ALLOSTERIC MODULATOR SAGE-217 IN MAJOR DEPRESSIVE DISORDER

    Oct 1, 2018, 00:00

  • PIH3 - CLINICAL AND DEMOGRAPHIC RISK FACTORS AND COSTS OF SURGICAL SITE INFECTION AFTER CAESAREAN SECTION

    Oct 1, 2018, 00:00

  • PHP298 - ON THE RIGHT TRACK? EXAMINING NICE’S FAST-TRACK APPRAISAL PROCESS

    Oct 1, 2018, 00:00

  • PHP308 - CONSIDERATION OF LEGAL ASPECTS IN HTA – CAN A SYSTEMATIC AND PRAGMATIC METHODOLOGICAL APPROACH BE IDENTIFIED IN GERMAN HTA?

    Oct 1, 2018, 00:00

  • PMD123 - CLINICAL, PATIENT-REPORTED OUTCOME MEASURES (PROMS) AND ECONOMIC OUTCOMES ASSOCIATED WITH ENHANCED RECOVERY PROGRAMS IN ELECTIVE HIP AND KNEE SURGERY IN EUROPE, THE MIDDLE EAST AND AFRICA- A SYSTEMATIC LITERATURE REVIEW

    Oct 1, 2018, 00:00

  • PND36 - COSTS OF MULTIPLE SCLEROSIS IN DENMARK- A REGISTER BASED STUDY

    Oct 1, 2018, 00:00

  • PMS41 - COST-EFFECTIVENESS ANALYSIS OF TOFACITINIB IN COMBINATION WITH METHOTREXATE IN THE TREATMENT OF MODERATE TO SEVERE RHEUMATOID ARTHRITIS IN GREECE

    Oct 1, 2018, 00:00

  • PHP155 - THE DEVELOPMENT AND EMPIRICAL APPLICATION OF A MULTIPLE SOCIETAL VALUE CRITERIA APPROACH TO RESOURCE ALLOCATION AMONG DISEASE CATEGORIES

    Oct 1, 2018, 00:00

  • PMD33 - BUDGET IMPACT ANALYSIS OF A DUAL-LAYER STENT RETRIEVER (DLSR) FOR THE TREATMENT OF PATIENTS WITH ACUTE ISCHEMIC STROKE (AIS) IN ENGLAND

    Oct 1, 2018, 00:00

  • PMS71 - SECULAR TRENDS IN THE INITIATION OF THERAPY IN SECONDARY FRACTURE PREVENTION IN EUROPE- A MULTI-NATIONAL STUDY INCLUDING DATA FROM DENMARK, SPAIN, AND THE UK.

    Oct 1, 2018, 00:00

  • PMS23 - OPTIMIZING TREATMENT FOR RHEUMATOID ARTHRITIS IN THE KINGDOM OF SAUDI ARABIA (OPTRA)

    Oct 1, 2018, 00:00

  • PMU28 - A CROSS INDICATION BUDGET IMPACT ANALYSIS OF SECUKINUMAB- A GREEK PERSPECTIVE

    Oct 1, 2018, 00:00

  • PRM27 - PREDICTING STABILITY OUTCOMES FOR FOSTERED CHILDREN USING MACHINE LEARNING- APPLICATION OF OUTCOME RESEARCH TO SOCIAL CARE

    Oct 1, 2018, 00:00

  • PCV34 - A REVIEW ASSESSING THE INCIDENCE AND PREVALENCE OF CHRONIC HEART FAILURE WITH PRESERVED EJECTION FRACTION

    Oct 1, 2018, 00:00

  • PCN371 - HEALTH RELATED QUALITY OF LIFE IN CERVIX-UTERI CANCER WOMEN TREATED IN A MEXICAN THIRD LEVEL PUBLIC FACILITY

    Oct 1, 2018, 00:00

  • PRS15 - A 10-YEAR FOLLOW-UP OF A COHORT OF PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) THROUGH A ONE-WAY MARKOV MODEL

    Oct 1, 2018, 00:00

  • PRS37 - ECONOMIC BURDEN ASSOCIATED WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)- A SYSTEMATIC LITERATURE REVIEW

    Oct 1, 2018, 00:00

  • PMD104 - COST-EFFECTIVENESS AND COST-UTILITY ANALYSIS OF TREATING DIABETIC FOOT ULCERS WITH URGOSTART COMPARED TO A NEUTRAL DRESSING.

    Oct 1, 2018, 00:00

  • PMH77 - ASSESSMENT OF HEALTH-RELATED QUALITY OF LIFE BY THE SF36V2 IN A PHASE 2, RANDOMIZED, PLACEBO-CONTROLLED TRIAL OF THE GABAA RECEPTOR POSITIVE ALLOSTERIC MODULATOR SAGE-217 IN MAJOR DEPRESSIVE DISORDER

    Oct 1, 2018, 00:00

  • PRM69 - AN INCREASE OVER TIME IN PUBLISHED REAL-WORLD AND HEALTH ECONOMIC EVIDENCE IN CLINICAL JOURNALS ACROSS LYSOSOMAL STORAGE DISORDERS

    Oct 1, 2018, 00:00

  • PHP130 - SICK-PAY EXPENDITURES IN HUNGARY BETWEEN 2005-2016

    Oct 1, 2018, 00:00

  • PSY20 - REAL WORLD TREATMENT PERSISTANCE OF GOLIMUMAB IN THE MANAGEMENT OF IMMUNE-MEDIATED RHEUMATIC DISEASES (IMRDS) IN EUROPE- A SYSTEMATIC LITERATURE REVIEW (SLR)

    Oct 1, 2018, 00:00

  • PND130 - MEASURING WHAT MATTERS TO PEOPLE WITH MULTIPLE SCLEROSIS AND PREFERENCES FOR NOVEL METHODS TO ASSESS CLINICAL OUTCOMES

    Oct 1, 2018, 00:00

  • PSS52 - THE BURDEN IN DIABETIC MACULAR EDEMA IN KOREA

    Oct 1, 2018, 00:00

  • PND26 - COST IMPLICATIONS OF A NOVEL WEIGHT DOSED TREATMENT FOR HIGHLY ACTIVE RELAPSING MULTIPLE SCLEROSIS IN PORTUGAL

    Oct 1, 2018, 00:00

  • PRM140 - UTILIZING ADVANCED DATA ANALYSIS AND VISUALIZATION, POWERED BY ARTIFICIAL INTELLIGENCE, TO ANALYZE PRICE MIGRATION DATA FOR ONCOLOGY PRODUCTS

    Oct 1, 2018, 00:00

  • PDB49 - TYPE 2 DIABETES MELLITUS IN ALGERIA – A COST OF ILLNESS STUDY

    Oct 1, 2018, 00:00

  • PHP287 - GERMAN EARLY BENEFIT ASSESSMENTS OF ORPHAN DRUGS UNDER FULL DOSSIER CONDITIONS

    Oct 1, 2018, 00:00

  • PIH15 - PREVALENCE OF DIAGNOSED UTERINE FIBROIDS AND ENDOMETRIOSIS IN THE US- DATA FROM A NATIONALLY REPRESENTATIVE POPULATION-BASED SURVEY

    Oct 1, 2018, 00:00

  • PMD118 - SEROLOGY TESTING IN SCHOOL-AGED CHILDREN WITH ASTHMA, IN THE UK, COULD LEAD TO SUBSTANTIAL COST SAVINGS FOR THE NHS- A POPULATION-BASED SIMULATION STUDY

    Oct 1, 2018, 00:00

  • PRS87 - COMPARABILITY OF A PROVISIONED DEVICE VERSUS BRING YOUR OWN DEVICE FOR COMPLETION OF PATIENT-REPORTED OUTCOME (PRO) MEASURES BY PARTICIPANTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)- QUALITATIVE INTERVIEW FINDINGS

    Oct 1, 2018, 00:00

  • PRM172 - LEARNINGS ON BRING YOUR OWN DEVICE UPTAKE FOR ECOA IMPLEMENTATION- A TALE OF TWO STUDIES

    Oct 1, 2018, 00:00

  • PCN33 - SYSTEMATIC LITERATURE REVIEW OF REAL-WORLD EVIDENCE (RWE) STUDIES FOR FIRST-LINE TREATMENTS IN ADVANCED OR METASTATIC RENAL CELL CARCINOMA

    Oct 1, 2018, 00:00

  • PCN82 - BUDGET IMPACT ANALYSIS OF ALECTINIB FOR THE TREATMENT OF PATIENTS WITH UNTREATED ALK-REARRANGED NSCLC IN ITALY

    Oct 1, 2018, 00:00

  • HT8 - DOES IQWIG MATTER? FREQUENCY OF DIVERGENT OPINIONS BETWEEN IQWIG AND THE G-BA

    Oct 1, 2018, 00:00

  • DS4 - A MULTI-DATABASE, MULTINATIONAL VALIDATION STUDY OF CARDIOVASCULAR DEATH, VENOUS THROMBOEMBOLIC EVENTS AND GASTROINTESTINAL DISEASES IN THE EU-ADR ALLIANCE

    Oct 1, 2018, 00:00

  • PND78 - SOCIO-ECONOMIC IMPACT OF DRAVET SYNDROME IN GERMANY- A REAL-WORLD STUDY

    Oct 1, 2018, 00:00

  • PHP119 - DISRUPTION IN PATIENT ACCESS TO INNOVATIVE THERAPY IN FRANCE AFTER INTERRUPTION OF NOMINATIVE TEMPORARY AUTHORISATION FOR USE

    Oct 1, 2018, 00:00

  • PMD47 - BUDGET IMPACT MODELLING OF POINT-OF-CARE HBA1C MONITORING OF PATIENTS WITH DIABETES MELLITUS TYPE II IN THE UNITED KINGDOM AND AUSTRALIA

    Oct 1, 2018, 00:00

  • PMS56 - COST-EFFECTIVENESS ANALYSIS OF SUBCUTANEOUS TOCILIZUMAB WITHOUT METHOTREXATE IN RHEUMATOID ARTHRITIS TREATMENT

    Oct 1, 2018, 00:00

  • PMS24 - COST MINIMIZATION ANALYSIS OF THIRD LINE RHEUMATOID ARTHRITIS DRUGS IN ECUADOR

    Oct 1, 2018, 00:00

  • PCP30 - COMPARISON REGARDING THE TRANSPARENCY OF REIMBURSEMENT DECISIONS FOR PHARMACEUTICALS USED TO TREAT DEPRESSION IN HUNGARY, ROMANIA, TURKEY AND CIS

    Oct 1, 2018, 00:00

  • PCN39 - ESTIMATING THE MEAN PROGRESSION-FREE SURVIVAL OF NIRAPARIB, OLAPARIB AND RUCAPARIB COMPARED TO ROUTINE SURVEILLANCE FOR THE MAINTENANCE TREATMENT OF ADULT PATIENTS WITH RECURRENT OVARIAN CANCER WITHOUT A BRCA MUTATION

    Oct 1, 2018, 00:00

  • PCV121 - PERFORMANCE INDICATORS OF CARDIAC REHABILITATION IN HUNGARY

    Oct 1, 2018, 00:00

  • PCN12 - COMPARATIVE ANALYSIS OF PROFILES OF STAGE IIIB/IV NSCLC PATIENTS BY TIME FROM DIAGNOSIS TO FIRST TREATMENT IN WESTERN EUROPE

    Oct 1, 2018, 00:00

  • PRM42 - COST MODEL OF SWITCHING FROM ENBREL TO ETANERCEPT BIOSIMILARS, FOR NON MEDICAL REASONS, IN RHEUMATOID ARTHRITIS PATIENTS IN SPAIN

    Oct 1, 2018, 00:00

  • PCN299 - A REVIEW OF APPRAISAL TIMELINES IN ONCOLOGY- DOES REIMBURSEMENT THROUGH THE CANCER DRUGS FUND (CDF) DELAY PATIENT ACCESS?

    Oct 1, 2018, 00:00

  • PIH40 - THE HEALTH LITERACY OF IRANIAN PARENTS- A SURVEY IN TEHRAN CAPITAL CITY

    Oct 1, 2018, 00:00

  • PND45 - CAREGIVER NEED ACROSS STAGES OF ALZHEIMER’S

    Oct 1, 2018, 00:00

  • PHP21 - METHODOLOGY OF IDENTIFICATION OF RISK GROUPS UNDER PHARMACEUTICAL GUIDELINES IN A SPECIAL REGIME INSURER IN COLOMBIA

    Oct 1, 2018, 00:00

  • PHP333 - ADDRESSING THE CHALLENGE OF CHRONICITY IN A REGION OF SPAIN. TAKING STEPS TOWARDS A PARTNERSHIP BETWEEN THE HEALTH CARE ADMINISTRATION AND THE PHARMACEUTICAL INDUSTRY

    Oct 1, 2018, 00:00

  • PMS69 - BIOSIMILAR AND ORIGINATOR INFLIXIMAB- INFLUENCE OF LOCAL POLICY MEASURES AND PRACTICES ON MARKET DYNAMICS BETWEEN SWEDISH COUNTIES

    Oct 1, 2018, 00:00

  • PRM270 - IMPACT OF THE CLINICAL TRIAL DESIGN STRATEGY ON PRODUCT MARKET UPTAKE AND OVERALL COMMERCIAL SUCCESS

    Oct 1, 2018, 00:00

  • PDB25 - PRESCRIBING PATTERN IN DIABETES MELLITUS PATIENTS IN SLOVENIA

    Oct 1, 2018, 00:00

  • PCV150 - HEALTH CARE RESOURCE USE AND QUALITY OF LIFE IN PATIENTS PRESCRIBED WITH SACUBITRIL/VALSARTAN IN PORTUGAL- A CROSS-SECTIONAL OBSERVATIONAL STUDY (PRIME STUDY)

    Oct 1, 2018, 00:00

  • PSY77 - ASSESSING THE IMPACT OF FORTIFYING PACKAGED INFANT CEREALS IN REDUCING THE BURDEN OF IRON DEFICIENCY ANEMIA IN PAKISTAN

    Oct 1, 2018, 00:00

  • PHP300 - HEALTH TECHNOLOGY ASSESSMENT ROADMAP FOR UKRAINE - THE PERSPECTIVE OF STAKHOLDERS ON CURRENT STATUS AND FUTURE OPPORTUNITIES

    Oct 1, 2018, 00:00

  • PRM128 - VALIDATION AND CONCEPTUAL DESIGN OF A HEALTH ECONOMIC MODEL FOR ANAEMIA TREATMENT IN MYELODYSPLASTIC SYNDROME

    Oct 1, 2018, 00:00

  • PMS77 - DECLINE IN HEALTHCARE RESOURCE CONSUMPTION FOR PATIENTS WITH RHEUMATOID ARTHRITIS STARTING CERTOLIZUMAB PEGOL THERAPY IN FRANCE (THE ECLAIR STUDY)

    Oct 1, 2018, 00:00

  • PCN137 - THE ECONOMIC EVALUATION OF IMATINIB COMBINED WITH CHEMOTHERAPY FOR PEDIATRIC PHILADELPHIA CHROMOSOME-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA IN CHINA

    Oct 1, 2018, 00:00

  • PCP60 - EVOLVING STRATEGIES FOR GENERATING, SYNTHESIZING, AND VISUALIZING REAL WORLD EVIDENCE IN RARE DISEASES

    Oct 1, 2018, 00:00

  • PUK39 - A CRITICAL APPRAISAL OF THE PRINCIPAL GUIDELINES FOR NEUROGENIC LOWER URINARY TRACT DYSFUNCTION USING THE AGREE II INSTRUMENT

    Oct 1, 2018, 00:00

  • PCN88 - NET IMPACT ANALYSIS OF IXAZOMIB IN COMBINATION WITH LENALIDOMIDE AND DEXAMETHASONE IN THE TREATMENT OF ADULTS WITH MULTIPLE MYELOMA FOR QUEBEC

    Oct 1, 2018, 00:00

  • PSY187 - THE QUANTITY AND QUALITY OF EVIDENCE SUPPORTING EUROPEAN MARKETING AUTHORISATION OF ORPHAN DRUGS- COMPARISON OF RARE ONCOLOGY VERSUS RARE DISEASE

    Oct 1, 2018, 00:00

  • PMS7 - LOSS OF QALYS ASSOCIATED WITH BIOSIMILAR DISCONTINUATION DUE TO NOCEBO EFFECT

    Oct 1, 2018, 00:00

  • PHP344 - AN ECONOMIC EVALUATION OF GENERIC DRUG ENTRIES IN TURKISH PHARMACEUTICAL MARKET

    Oct 1, 2018, 00:00

  • PHP339 - MINIMALLY IMPORTANT DIFFERENCE (MID) OF EQ-5D-5L INDEX SCORE IN HONG KONG ADULTS POPULATION USING HONG KONG SCORING ALGORITHM

    Oct 1, 2018, 00:00

  • PHP232 - A COMPARISON OF COST-EFFECTIVENESS ASSESSMENTS BETWEEN NICE AND SMC TECHNOLOGY APPRAISALS

    Oct 1, 2018, 00:00

  • PSS54 - ETHICAL VALIDATION PROCESS FOR VIDEO RECORDED QUALITATIVE INTERVIEWS- EXPERIENCE FROM A RESEARCH PROJECT IN DERMATOLOGY IN FRANCE AND CANADA

    Oct 1, 2018, 00:00

  • PND148 - DEVELOPMENT OF A DIGITAL APP AND INNOVATIVE RECRUITMENT FOR AN INTERNATIONAL REAL-WORLD OBSERVATIONAL STUDY IN CHARCOT MARIE TOOTH DISEASE

    Oct 1, 2018, 00:00

  • PCN190 - COST-EFFECTIVENESS OF NIVOLUMAB + IPILIMUMAB IN FIRST-LINE TREATMENT OF ADVANCED OR METASTATIC RENAL CELL CARCINOMA IN THE NETHERLANDS

    Oct 1, 2018, 00:00

  • PHP145 - NUMBER OF PHARMACISTS IN EUROPEAN COUNTRIES BETWEEN 2000-2015

    Oct 1, 2018, 00:00

  • PMS31 - SECUKINUMAB AS A MORE EEFICIENT ALTERNATIVE FOR ANKYLOSING SPONDYLITIS TREATMENT- A COST PER RESPONDER ANALYSIS FROM KOREAN PERSPECTIVE

    Oct 1, 2018, 00:00

  • PCN128 - COSTS OF HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT) IN PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA (ALL), DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) AND FOLLICULAR LYMPHOMA (FL) – A RETROSPECTIVE ANALYSIS OF JAPANESE CLAIMS DATA

    Oct 1, 2018, 00:00

  • PHP210 - DEVELOPMENT OF DRUG INNOVATIVNESS ASSESSMENT TOOL FOR DECISION-MAKING IN REIMBURSEMENT AND PRICING

    Oct 1, 2018, 00:00

  • PND144 - REPORTED QUALITY OF LIFE IN PEOPLE WITH MULTIPLE SCLEROSIS UNDER LONG TERM TREATMENT WITH FAMPRIDINE

    Oct 1, 2018, 00:00

  • PHP160 - PRESCRIPTION CHARGES IN SCOTLAND- THE IMPACT OF FREE PRESCRIPTIONS

    Oct 1, 2018, 00:00

  • PCN92 - THE EVALUATION OF THE ECONOMIC EFFICIENCY OF LENVATINIB IN COMBINATION WITH EVEROLIMUS IN RUSSIAN PATIENTS WITH DISSEMINATED RENAL CELL CARCINOMA

    Oct 1, 2018, 00:00

  • PCV24 - SAFETY AND EFFECTIVENESS OF CONTEMPORARY P2Y12 INHIBITORS IN EAST ASIAN PATIENTS WITH ACUTE CORONARY SYNDROMES- A NATIONWIDE POPULATION-BASED COHORT STUDY

    Oct 1, 2018, 00:00

  • PCN180 - PHARMACOECONOMIC ASSESSMENT OF FULVESTRANT VERSUS DD (DOXORUBICIN, DOCETAXEL) THERAPY IN POSTMENOPAUSAL WOMEN WITH METASTATIC ER (+) HER2 (-) BREAST CANCER IN UKRAINE

    Oct 1, 2018, 00:00

  • PHP103 - OUT-OF-POCKET EXPENDITURE FOR PRESCRIBED AND OVER-THE-COUNTER MEDICATIONS IN GREECE

    Oct 1, 2018, 00:00

  • PHP292 - ROADMAP FOR IMPLEMENTATION OF HEALTH TECHNOLOGY ASSESSMENT IN ROMANIA

    Oct 1, 2018, 00:00

  • PCV94 - NUTILIS CLEAR® IN DYSPHAGIC ADULT STROKE PATIENTS WITH ASPIRATION OF 10–14 POINTS ON GUSS SCALE

    Oct 1, 2018, 00:00

  • PRM175 - EQ-5D-3L VS. EQ-5D-5L- A CROSS-SECTIONAL COMPARISON OF MEASUREMENT PROPERTIES AMONG TOTAL HIP AND KNEE REPLACEMENT PATIENTS

    Oct 1, 2018, 00:00

  • PSY41 - OVERALL SURVIVAL AND NON-RELAPSE MORTALITY OF PATIENTS WITH CHRONIC GRAFT-VERSUS-HOST DISEASE- A SYSTEMATIC LITERATURE REVIEW

    Oct 1, 2018, 00:00

  • PMS48 - COST PER RESPONDER ANALYSIS FOLLOWING A 24-WEEK PSORIATIC ARTHRITIS TREATMENT WITH SECUKINUMAB VERSUS ETANERCEPT FROM THE PORTUGUESE PAYER PERSPECTIVE

    Oct 1, 2018, 00:00
  • «
  • 51
  • 52
  • 53 (current)
  • 54
  • 55
  • 56
  • 57
  • 58
  • 59
  • 60
  • »